Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival.

Breast Cancer (Auckl) · 2014 · PMC4022699 · PMID 24855372

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

29 Furthermore, there was a strong trend toward an overall survival benefit with the addition of pertuzumab to trastuzumab and docetaxel as there have been fewer deaths in the pertuzumab group compared to the non-pertuzumab group (17.2 vs. 23.6%).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.